Aktiesnakken — November 2015
-
Regnskabet fejler ikke noget i RTX.
-
Rbrew opjusterer forventningerne til årets resultat og øger målsætning for EBIT-margin på mellemlang sigt til 15%
-
God morgen.

-
God morgen

-
BB mener at Arzerra kan få comeback. Han spekulerer I at Novartis vil designe et nyt og bedre studie (det annulerede var et GS
K studie som Novartis arvede) -
MUFC...Forkert chat.

-
sorry begynderfejl
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind